Product Description
1. Technical Specifications
| Attribute |
Details |
| Brand Name |
Cyramza Injection |
| Generic Name |
Ramucirumab |
| Strength |
500 mg/50 mL (10 mg/mL) |
| Dosage Form |
Intravenous Infusion (concentrate for solution) |
| Packaging Size |
Single-use vial (commonly 50 mL) |
| Packaging Type |
Glass vial with sterile solution |
| Medicine Type |
Anticancer (Monoclonal Antibody VEGFR-2 Antagonist) |
| Manufacturer |
Eli Lilly and Company |
| Distributed By |
Authorized oncology medicine distributors / pharmacies |
2. Product Description
Cyramza (Ramucirumab) is a recombinant human IgG1 monoclonal antibody that specifically binds to VEGFR-2 (vascular endothelial growth factor receptor 2) and blocks its activation by ligands.
By inhibiting VEGFR-2, it prevents angiogenesis (formation of new blood vessels) that tumors need for growth and metastasis.
It is used either alone or in combination with chemotherapy in various advanced or metastatic cancers.
3. Product Highlights
| Attribute |
Details |
| Therapeutic Category |
Anticancer Angiogenesis Inhibitor (Monoclonal Antibody) |
| Application Area |
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma |
| Mechanism of Action |
Selectively binds VEGFR-2 blocks VEGF ligands inhibits angiogenesis & tumor blood supply |
| Administration |
Intravenous infusion, typically every 2 weeks (dosage individualized) |
| Storage Conditions |
Refrigerate at 28 C. Do not freeze. Protect from light. |
4. Therapeutic Uses
-
Metastatic gastric or gastroesophageal junction adenocarcinoma (as monotherapy or with paclitaxel).
-
Metastatic colorectal cancer (in combination with FOLFIRI after prior therapy with bevacizumab, oxaliplatin, and fluoropyrimidine).
-
Non-small cell lung cancer (NSCLC) (in combination with docetaxel after progression on platinum-based chemotherapy).
-
Hepatocellular carcinoma (HCC) in patients previously treated with sorafenib.
5. Side Effects
Common:
-
Hypertension
-
Headache, fatigue
-
Diarrhea, abdominal pain
-
Proteinuria
-
Epistaxis, bleeding gums
Serious / Severe:
-
Severe bleeding/hemorrhage (GI bleeding, pulmonary hemorrhage)
-
Arterial thromboembolic events (stroke, myocardial infarction)
-
Gastrointestinal perforation
-
Impaired wound healing
-
Infusion-related reactions (flushing, dyspnea, chest pain)
-
Severe hypertension, hypertensive crisis
6. Precautions
-
Bleeding Risk: Avoid in patients with recent hemorrhage; monitor for signs of bleeding.
-
Hypertension: Regularly monitor blood pressure; treat as needed.
-
Proteinuria: Monitor urine protein before and during therapy; discontinue if nephrotic syndrome develops.
-
Surgery/Wound Healing: Withhold treatment before and after surgery until adequate wound healing occurs.
-
Pregnancy & Breastfeeding: Contraindicated; risk of fetal harm. Breastfeeding not recommended.
-
Infusion Reactions: Premedication with antihistamines recommended to reduce hypersensitivity risk.
-
Liver Function: Monitor closely in patients with HCC and underlying cirrhosis.
Accurate Cancer Treatment for AdultsCyramza 500 mg Injection offers advanced treatment options for adult cancer patients, providing a targeted approach as part of comprehensive therapy regimes. It must be administered by healthcare professionals, ensuring that patients receive the most suitable care tailored to their condition. The injectable form ensures rapid absorption and effectiveness in clinical settings.
Professional Distribution across IndiaAs a trusted distributor, exporter, supplier, trader, and wholesaler in India, we guarantee the delivery of authentic Cyramza 500 mg Injection to authorized medical practitioners and centers. Our network is committed to maintaining the products quality and safety from storage through transportation, ensuring that healthcare providers receive reliable supplies for their patients.
FAQs of Cyramza 500 Mg Injection:
Q: How should Cyramza 500 mg Injection be stored?
A: Cyramza 500 mg Injection should always be stored in a cool and dry place, away from direct sunlight and extreme temperatures, in order to maintain its stability and effectiveness.
Q: What is the recommended usage process for Cyramza 500 mg Injection?
A: The injection must be administered by a qualified healthcare professional, such as a doctor, and strictly according to prescribed dosage and schedule for adult patients, as determined by individual medical needs.
Q: When is Cyramza 500 mg Injection typically given during treatment?
A: Cyramza 500 mg Injection is usually given at regular intervals, as part of a broader cancer treatment plan, with timing determined by your oncologist based on your specific health status and response to therapy.
Q: Where can Cyramza 500 mg Injection be sourced in India?
A: This medication is available through reputable distributors, exporters, suppliers, traders, and wholesalers across India, but should only be procured by licensed medical professionals or healthcare facilities.
Q: What are the key benefits of using Cyramza 500 mg Injection?
A: Cyramza 500 mg Injection provides targeted cancer therapy, potentially improving treatment outcomes for adults with certain cancers, under professional supervision, thereby contributing to more effective and monitored patient care.
Q: Is Cyramza 500 mg Injection suitable for self-administration?
A: No, Cyramza 500 mg Injection is not suitable for self-administration and should only be given by trained medical staff, ensuring safety and correct dosage during cancer treatment.
Send Email 
Send Inquiry
Send Inquiry
Send SMS
English
Spanish
French
German
Italian
Chinese (Simplified)
Japanese
Korean
Arabic
Portuguese